GYRE · Company research
Gyre Therapeutics, Inc. Common Stock (GYRE): Valuation Analysis
Available valuation snapshots and ratios; unavailable metrics remain blank.
RESEARCH CONTEXT
Understand the numbers
Available valuation snapshots and ratios; unavailable metrics remain blank. Use period, currency, units and source fields when interpreting values.
1records availableHealthcare
Valuation Analysis data
Database-backed records only
| valuation date | price | market cap | enterprise value | pe | forward pe | peg | price sales | price book | price fcf |
|---|---|---|---|---|---|---|---|---|---|
| Oct 8, 2026 | 7.04 | $753,775,616.51 | 710488616.51 | 5.9661016949152542 | — | — | 25.8984922353547500 | 4.0233767808208210 | — |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.